WEKO3
アイテム
NSC-3852 synergistically enhances the cytotoxicity of olaparib in oral squamous cell carcinoma
http://hdl.handle.net/10069/0002001743
http://hdl.handle.net/10069/00020017434d117f43-8a58-49fd-baed-a1b0fbd0bc38
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
BBRC744_151166.pdf (1.2 MB)
Download is available from 2025/12/19.
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-01-09 | |||||||||||||||||||
| タイトル | ||||||||||||||||||||
| タイトル | NSC-3852 synergistically enhances the cytotoxicity of olaparib in oral squamous cell carcinoma | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 言語 | ||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | PARP1 | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | Olaparib | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | Poly ADP-Ribosylation | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | NSC-3852 | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 主題Scheme | Other | |||||||||||||||||||
| 主題 | HDAC inhibitors | |||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||
| 資源タイプ | journal article | |||||||||||||||||||
| 著者 |
Sasaki, Yuka
× Sasaki, Yuka
× Inouchi, Takuma
× Kise, Chie
× Nakatsuka, Ryusuke
× Inoue, Amane
× Masutani, Mitsuko
× Nozaki, Tadashige
|
|||||||||||||||||||
| 抄録 | ||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||
| 内容記述 | The PARP inhibitor olaparib is an anti-cancer agent based on synthetic lethality that targets poly (ADP-ribose) polymerases. It is used as a therapeutic agent for breast, ovarian, pancreatic, and prostate cancers carrying BRCA1/2 mutations that cause deficiency in homologous recombination. In recent years, acquired resistance to PARP inhibitors has become a clinical problem in PARP inhibitor-treated patients. Meanwhile, the development of molecular targeted drugs for highly malignant oral cancers has not progressed, and effective treatment strategies are needed. In this study, we identified the histone deacetylase inhibitor NSC-3852 as a compound that synergistically enhances the effects of olaparib in oral squamous cell carcinoma cell lines. N-Acetyl-l-cysteine treatment partially recovered cell survival after co-treatment with olaparib and NSC-3852. Moreover, the combination of olaparib and NSC-3852 rapidly upregulated γH2AX at 2 h after treatment, and induced S-phase arrest and apoptosis at 24 h after treatment, suggesting that this combination induced apoptosis through accumulation of massive DNA damage. Taken together, these findings demonstrate that NSC-3852 is a sensitizer of olaparib and suggest that the combination of NSC-3852 and olaparib may be a useful therapeutic strategy for homologous recombination-proficient cancers, including cancers with acquired resistance to olaparib and high-grade oral squamous cell carcinoma. | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 書誌情報 |
en : Biochemical and Biophysical Research Communications 巻 744, p. art. no. 151166, 発行日 2024-12-19 |
|||||||||||||||||||
| 出版者 | ||||||||||||||||||||
| 出版者 | Elsevier Inc. | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| ISSN | ||||||||||||||||||||
| 収録物識別子タイプ | ISSN | |||||||||||||||||||
| 収録物識別子 | 0006291X | |||||||||||||||||||
| DOI | ||||||||||||||||||||
| 関連タイプ | isIdenticalTo | |||||||||||||||||||
| 識別子タイプ | DOI | |||||||||||||||||||
| 関連識別子 | 10.1016/j.bbrc.2024.151166 | |||||||||||||||||||
| 権利 | ||||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 権利情報 | © 2024 Elsevier Inc. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/. | |||||||||||||||||||
| 著者版フラグ | ||||||||||||||||||||
| 出版タイプ | AM | |||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||||||||||
| 引用 | ||||||||||||||||||||
| 内容記述タイプ | Other | |||||||||||||||||||
| 内容記述 | Biochemical and Biophysical Research Communications, 744, art. no. 151166; 2024 | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
